Expert Analysis

Improving HCV Therapy in 2006

Source: CCO Independent Conference Coverage of the 2006 Annual Meeting of the European Association for the Study of the Liver*

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.

Improving HCV Therapy in 2006

Faculty:

Nezam H. Afdhal, MD, FRCPI
Peter Ferenci, MD
Stephanos J. Hadziyannis, MD

CME CREDIT INFORMATION

Release Date: 06/29/06

Expiration Date: 06/28/07

Physicians: maximum of 2.0 AMA PRA Category 1 Credits™

Status: Please log in to view status

Learning Objectives

Upon completion of this activity, participants should be able to:

Discuss data from studies of novel drugs for the treatment of patients with hepatitis C virus (HCV)
Recount strategies for improving the current treatment and outcomes of patients with HCV
Review the results of studies evaluating the treatment of nonresponders and patients with HCV genotype 1

Topics covered include:

New Agents in Development: Viramidine
Pharmacokinetic Enhancement of Novel HCV Protease Inhibitor Plasma Concentrations
Resistance Characteristics of HCV Protease Inhibitor VX-950
Combination VX-950 and Peginterferon Alfa-2a Therapy for HCV Infection
HCV Polymerase Inhibitor Valopicitabine
HCV Polymerase Inhibitor R1626
Toll-Like Receptor (TLR) Agonists
Gene-Shuffled Interferon Alfa for the Treatment of HCV Infection
Albumin Interferon Alfa-2b for the Treatment of HCV Infection
Oral Platelet Growth Factor Eltrombopag
Tailoring HCV Therapy With Ribavirin Dose and Treatment Duration
Predictors of Fibrosis Progression
Treatment of Nonresponders: The REPEAT Study
Treatment of Nonresponders With Novel HCV Polymerase Inhibitor Valopicitabine
Treatment of Nonresponders With Combination SCH-503034 Plus Peginterferon Alfa-2b
Treatment of Nonresponders With Novel Interferon Albumin Interferon Alfa-2b
Impact of Posttransplant Treatment of HBV/HIV-Infected Patients vs No Treatment of HCV/HIV-Infected Patients Posttransplant

Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.